GL1X · GenesisL1 explorer

Research workbench

Structure of the EC2 domain of CD9 in complex with nanobody 4E8

Analyse Structure of the EC2 domain of CD9 in complex with nanobody 4E8 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6Z1V
Type
protein
Length
203 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
CD9 antigen; Nanobody 4E8
UniProt
P21926

Structure

x-ray diffraction · 2 distinct chains · 30% helix, 31% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ACD9 antigenprotein8064% helix, 4% strandP21926
BNanobody 4E8protein1237% helix, 48% strand—

Ligands and binding sites

  • PGE · Triethylene glycol · additive · chains A
  • EDO · 1,2-ethanediol · additive · chains A, B
  • ACY · Acetic acid · additive · chains B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Interfaces

1 interface between chains.

  • A–B · 680 Ų buried · 11 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 3 disulfide (disulfide).

Compared structures

  • 6Z1V · Structure of the EC2 domain of CD9 in complex with nanobody 4E8 · the same entry in another collection · chain A against A, TM-score 1.00
  • P21926 · AlphaFold monomer V2.0 prediction for CD9 antigen (P21926) · a predicted model of the same protein · chain A against A, TM-score 0.72

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.